Dopamine receptors and schizophrenia: Contribution of molecular genetics and clinical neuropsychology

International Journal of Neuropsychopharmacology

Volumn 2, Issue 3, 1999, Pages 197-227

  Emilien, Gérard ^a,c   Maloteaux, Jean Marie ^a   Geurts, Muriel ^a   Owen, Michael J ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c NONE   (France)

Author keywords

Antipsychotics; Clinical neuropsychology; Cognition; Dopamine receptors; Memory; Molecular genetics; Neuroleptics; Schizophrenia

Indexed keywords

EID: 0000994440     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145799001479     Document Type: Article

References (201)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1988). Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. American Journal of Psychiatry 155, 761-767.
2. Alpert M, Clark A, Pouget ER (1994). The syntactic role of pauses in the speech of schizophrenic patients with alogia. Journal of Abnormal Psychology 103, 750-757.
3. Andreasen NC (1979). Thought, language and communication disorders : diagnostic significance. Archives of General Psychiatry 36, 1325-1330.
4. Andreasen NC, Rezai K, Alliger R, Swayze VW, Flaum M, Kirchner P, Cohen G, O'Leary DS (1992). Hypofrontality in neuroleptic-native patients and in patients with chronic schizophrenia: assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Archives of General Psychiatry 49, 943-958.
5. Antonarakis SE, Blouin J-E, Pulver AE, Wolyniec P, Lasseter VK, Nestadt G, Kasch L, Babb R, Kazazian HH, Dombroski B, Kimberland M, Ott J, Housman D, Karayiorgou M, MacLean CJ (1995). Schizophrenia susceptibility and chromosome 6p by multipoint affected sib-pair linkage analysis. Nature Genetics 11, 235-236.
6. Asghari V, Schoots O, Van Kats S, Ohara K, Jovanovic V, Guan H-C, Bunzow JR, Petronis A, Van Tol HHM (1994). The dopamine D4 receptor repeat: analysis of different native and mutant forms of the human and rat gene. Molecular Pharmacology 46, 364-373.
7. Asherton P, Mant R, Holmans P, Williams J, Cardno A, Murphy K, Jones L, Collier D, McGuffin P, Owen MJ (1996). Linkage association and mutational analysis of the dopamine D3 receptor gene in schizophrenia. Molecular Psychiatry 1 (2), 125-132.
8. Baddeley AD, Logie R, Nimmo-Smith J, Brereton N (1985). Components of fluent reading. Journal of Memory and Language 24, 119-131.
9. Barch DM, Berenbaum H (1997). The effect of language production manipulations on negative thought disorder and discourse coherence disturbances in schizophrenia. Psychiatry Research 71, 115-127.
10. Beatty WW, Jocic Z, Monson N, Staton RD (1993). Memory and frontal lobe dysfunction in schizophrenia and schizoaffective disorder. Journal of Nervous and Mental Disease 181, 448-453.
11. Bellack AS (1992). Cognitive rehabilitation for schizophrenia: Is it possible? Is it necessary? Schizophrenia Bulletin 18 (1), 43-50.
12. Berenbaum H, Barch DM (1995). The categorization of thought disorder. Journal of Psycholinguistic Research 24, 349-376.
13. Berman I, Viegner B, Merson A, Allan E, Pappas D, Green AI (1997). Differential relationship between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophrenia Research 25, 1-10.
14. Berman KF, Zec RF, Weinberger DR (1986). Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. II. Role of neuroleptic treatment, attention and mental effort. Archives of General Psychiatry 43, 126-135.
15. Brébion G, Amador X, Smith MJ, Gorman JM (1997). Mechanisms underlying memory impairment in schizophrenia. Psychological Medicine 27, 383-393.
16. Brenner HD, Hodel B, Roder V, Corrigan P (1992). Treatment of cognitive dysfunctions and behavioral deficits in schizophrenia. Schizophrenia Bulletin 18 (1), 21-26.
17. 2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects. Pharmacopsychiatry 31, 159-162.
18. Buchanan RW, Holstein C, Breier A (1994). The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biological Psychiatry 36, 717-725.
19. Caldwell CB, Gottesman II (1992). Schizophrenia, a high risk factor for suicide : clues to risk reduction. Suicide and Life-Threatening Behavior 22, 479-493.
20. Cannon TD, Kaprio J, Lönnqvist J, Huttunen M, Koskenvuo M (1998). The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study. Archives of General Psychiatry 55, 67-74.
21. Carlson RA, Sullivan MA, Schneider W (1989). Practice and working memory effects in building procedural skills. Journal of Experimental Psychology : Learning, Memory and Cognition 15, 517-526.
22. Cassens G, Inglis AK, Applebaum PS, Gutheil TG (1990). Neuroleptics : effects on neuropsychological function in chronic schizophrenic patients. Schizophrenia Bulletin 16, 477-499.
23. 2 receptor. Journal of Neurochemistry 60, 372-375.
24. Chai B, Meltzer HY. The effect of chronic clozapine on basal dopamine release and apomorphine-induced DA release in the striatum and nucleus accumbens as measured by in vivo brain microdialysis. Neuroscience Letters 140, 47-50.
25. Civelli O (1995). Molecular biology of the dopamine receptor subtypes. In: Bloom FE, Kupfer DJ (Eds.), Psychopharmacology : the Fourth Generation of Progress (pp. 155-161). New York: Raven Press.
26. Classen, W, Laux G (1988). Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol or clozapine. Pharmacopsychiatry 21, 295-297.
27. Coon H, Holik J, Hoff M, Reimherr F, Wender P, Myles-Worsley M, Waldo M, Freedman R, Byerley W. (1994). Analysis of chromosome 22 markers in nine schizophrenia pedigrees. American Journal of Genetics 54, 72-79.
28. Cornblatt B, Keilp J (1994). Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophrenia Bulletin, 20, 31-46.
29. Cornblatt B, Obuchowski M, Schnur D, O'Brien JD (1998). Hillside study of risk and early detection in schizophrenia. British Journal of Psychiatry 172 (Suppl. 33), 26-32.
30. Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L (1989). The Continuous Performance Test, Identical Pairs Version. II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Research 29, 65-85.
31. Coward DM (1992). General pharmacology of clozapine. British Journal of Psychiatry 168 (Suppl. 17), 5-11.
32. Crocq MA, Mant R, Asherson P, Williams J, Hode Y, Mayerova A, Collier D, Lannfelt L, Sokoloff P, Schwartz JC, Gill M, Macher JP, McGuffin P, Owen M (1992). Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. Journal of Medical Genetics 29, 858-860.
33. Crow TJ (1980). Molecular pathology of schizophrenia: more than one disease process? British Journal of Medicine 280, 66-68.
34. Cutler NR, Veroff AE, Frackiewicz EJ, Welke TL, Kurtz NM, Sramek JJ (1996). Assessing the neuropsychological profile or stable schizophrenic outpatients. Journal of Neuropsychiatry 8 (4), 423-428.
35. d'Amato T, Saoud M, Triboulet P, Bertaud JP, Dalery J (1998). Vulnérabilité à la schizophrénie. I. Nature familiale des indicateurs neuropsychologiques. L'Encéphale 24, 442-448.
36. Daniels JK, Spurlock G, Williams NM, Cardno AG, Jones LA, Murphy KC, Asherson P, Holmans, P, Fenton I, McGuffin P, Owen MJ (1997). Linkage study of chromosome 6p in Sib-Pairs with schizophrenia. American Journal of Medical Genetics (Neuropsychiatric Genetics) 74, 319-323.
37. Davis KL, Kahn RS, Ko G, Davidson M (1991). Dopamine in schizophrenia: a review and reconceptualization. American Journal of Psychiatry 148, 1474-1486.
38. Docherty NM, Miller TN, Lewis MA (1997). Communication disturbances in the natural speech of schizophrenic patients and non-schizophrenic parents of patients. Acta Psychiatrica Scandinavica 95, 500-507.
39. Dohlman HG, Caron MG, Lefkowitz RJ (1987). A family of receptors coupled to guanine nucleotide regulatory proteins. Biochemistry 26, 2657-2664.
40. Dubertret C, Gorwood P, Ades J, Feingold J, Schwartz JC, Sokoloff P (1998). Meta-analysis of DRD3 gene and schizophrenia: ethnic heterogeneity and significant association in Caucasians. American Journal of Medical Genetics 81 (4), 318-322.
41. Durany N, Thome J, Palomo A, Foley P, Riederer P, Cruz-Sanchez FF (1996). Homozygosity at the dopamine D3 receptor gene in schizophrenic patients. Neuroscience Letters 220, 151-154.
42. Farde L, Gustavsson JP, Jönsson E (1997). D2 dopamine receptors and personality traits. Nature 385, 590.
43. Farde L, Nordstrom A (1992). PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. British Journal of Psychiatry (Suppl.), 30-33.
44. 3 dopamine receptor generated by alternative splicing in the third cytoplasmic loop. Journal of Biological Chemistry 268, 5872-5878.
45. Fletcher PC, McKenna PJ, Frith CD, Grasby PM, Friston KJ, Dolan RJ (1998). Brain activations in schizophrenia during a graded memory task studied with functional neuroimaging. Archives of General Psychiatry 55, 1001-1008.
46. Folstein MF, Folstein SE, McHugh PR (1975). 'Mini-Mental state': a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12, 189-198.
47. Franke P, Maier W, Hain C, Klinger T (1992). Wisconsin Card Sorting Test : an indicator of vulnerability to schizophrenia. Schizophrenia Research 6, 243-249.
48. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerely W (1997). Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proceedings of the National Academy of Sciences, USA 94, 587-592.
49. Fujiwara Y, Yamaguchi K, Tanaka Y, Tomita H, Shiro Y, Kashihara K, Sato K, Kuroda S (1997). Polymorphism of dopamine receptors and transporter genes in neuropsychiatric diseases. European Neurology 38 (Suppl. 1), 6-10.
50. Gabrielli JDE (1998). Cognitive neuroscience of human memory. Annual Review of Psychology 49, 87-115.
51. 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel®) in patients with schizophrenia. Psychopharmacology 135, 119-126.
52. Gill M, Vallada H, Collier D, Sham P, Holmans P, Murray R, McGuffin P, Nanko S, Owen M, Antonarakis S, Housman D, Kazazian H, Nestadt G, Pulver AE, Straub RE, MacLean CJ, Walsh D, Kendler KS, DeLisi L, Polymeropoulos M, Coon H, Byerley W, Lofthouse R, Gershon E, Read CM, et al. (1996). A combined analysis of D22S278 marker alleles in affected sibpairs : support for a susceptibility locus for schizophrenia at chromosome 22q12. American Journal of Medical Genetics (Neuropsychiatric Genetics), 67, 40-45.
53. Gold J, Harvey PD (1993). Cognitive deficits in schizophrenia. In: Powchik P, Schultz SC (Eds.), Psychiatric Clinics of North America (pp. 295-312). Philadelphia: William B Saunders.
54. Gold JM, Randolph C, Carpenter CJ, Goldberg TE, Weinberger DR (1992). Forms of memory failure in schizophrenia. Journal of Abnormal Psychology 101, 487-494.
55. Goldberg TE, Aloia MS, Gourovitch ML, Missar D, Pickar D, Weinberger DR (1998). Cognitive substrates of thought disorder. I. The semantic system. American Journal of Psychiatry 155, 1671-1676.
56. Goldberg TE, Gold JM (1995). Neurocognitive deficits in schizophrenia. In : Hirsch SR, Weinberger DR (Eds.), Schizophrenia. London, England: Blackwell Science Ltd.
57. Goldberg TE, Hyde TM, Kleinman JE, Weinberger DR. I (1993). Course of schizophrenia: neuropsychological evidence for a static encephalopathy. Schizophrenia Bulletin 19, 797-804.
58. Goldberg TE, Torrey ES, Gold JM, Ragland JE, Bigelow LC, Weinberger DR (1993). Learning and memory in monozygotic discordant for schizophrenia. Psychological Medicine 23, 71-85.
59. Goldman-Rakic PS (1995). Cellular basis of working memory. Neuron 14, 477-485.
60. Goldsmith SK, Shapiro RM, Joyce JN (1997). Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. Archives of General Psychiatry 54 (7), 649-658.
61. Goldstein JM, Seidman LJ, Goodman J, Koren D, Lee H, Weintraub S, Tsuang MT (1998). Are there sex differences in neuropsychological functions among patients with schizophrenia? American Journal of Psychiatry 155, 1358-1364.
62. Gottesman II (1993). Origins of schizophrenia: past and prologue. In: Plomin R, McLean GE (Eds.), Nature, Nurture and Psychology (pp. 231-244). Washington, DC: American Psychological Association.
63. Grace AA (1991). Phasic versus tonic dopamine release and the modulation of dopamine system responsivity : a hypothesis for the etiology of schizophrenia. Neuroscience 41, 1-24.
64. Green MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 153 (3), 321-330.
65. Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J (1997). Does risperidone improve verbal working memory in treatment-resistant schizophrenia? American Journal of Psychiatry 154 (6), 799-804.
66. Griffon N, Sokoloff P, Diaz J, Levesque D, Sautel F, Schwartz J-C, Simon P, Costentin J, Garrido F, Mann A, Wermuth C (1995). The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches. European Neuropsychopharmacology 5 (Suppl.), 3-9.
67. Grove WM, Lebow BS, Clementz BA, Cerri A, Medus C, Iacono WG (1991). Familial prevalence and coaggregation of schizotypy indicators: a multitrait family study. Journal of Abnormal Psychology 100, 115-121.
68. Gurling H, Kalsi G, Chen AH, Green M, Butler R, Read T, Murphy P, Curtis D, Sharma T, Petursson H, Brynjolfsson J (1995). Schizophrenia susceptibility and chromosome 6p24-22. Nature Genetics 11, 234-235.
69. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY (1993). Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry, 34, 702-712.
70. Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A (1987). The Vermont Longitudinal Study of Persons with Severe Mental Illness. I. Methodology, study sample, and overall status 32 years later. American Journal of Psychiatry 144, 718-726.
71. Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC, Hoblyn J, Davis KL (1998). Symptoms, cognitive functioning and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. American Journal of Psychiatry 155 (8), 1080-1086.
72. Harvey PD, Lenzeneger MF, Keefe RSE, Pogge DL, Serper MR, Mohs RC (1992). Empirical assessment of the factorial structure of clinical symptoms in schizophrenic patients: formal thought disorder. Psychiatry Research 44, 141-151.
73. Harvey PD, White L, Parrella M, Putnam KM, Kincaid MM, Powchik P, Mohs RC, Davidson M (1995). The longitudinal stability of cognitive impairment in schizophrenia. Mini-Mental scores at one-and two-year follow-ups in geriatric in-patients. British Journal of Psychiatry 166, 630-033.
74. Hauser ER, Boehnke M, Guo SW, Risch N (1996). Affected sib-pair interval mapping and exclusion for complex genetic traits: sampling considerations. Genetic Epidemiology 13, 117-138.
75. Heaton RK (1981). Wisconsin Card Sorting Test Manual. Odessa, FL: Psychological Assessment Resources.
76. Heaton RK, Drexler M (1987). Clinical and neuropsychological findings in schizophrenia and aging. Miller NE, Cohen CD (Eds.). In : Schizophrenia and Aging: Schizophrenia, Paranoia, and Schizophreniform Disorders in Later life (pp. 145-161). New York: Guildford.
77. Heinz A, Knable MB, Weinberger DR (199-6). Doparnine D2 receptor imaging and neuroleptic drug response. Journal of Clinical Psychiatry, 57, 84-88.
78. Heritch AJ (1990). Evidence for reduced and dysregulated turnover of dopamine in schizophrenia. Schizophrenia Bulletin 16 (4), 605-615.
79. Hirsch SR, Weinberger DR (Eds.) (1994). Schizophrenia, London, Blackwood Press.
80. Hoff AL, Harris D, Faustman WO, Beal M, DeVilliers D, Mone RD, Moses JA, Csernansky JG (1996). A neuropsychological study of early onset schizophrenia. Schizophrenia Research 20, 21-28.
81. Hoff AL, Riordan H, O'Donnell DW, Morris L, DeLisi LE (1992). Neuropsychological functioning of first-episode schizophreniform patients. American Journal of Psychiatry 149, 898-903.
82. Holzman PS, Solomon CM, Levin S, Waternaux CS (1984). Pursuit eye movement dysfunctions in schizophrenia. Family evidence for specificity. Archives of General Psychiatry 41, 136-139.
83. Hyde T, Nawroz S, Goldberg TE, Bigelow LB, Strong D, Ostrem JL, Weinberger DR, Kleinman JE (1994). is there cognitive decline in schizophrenia? British Journal of Psychiatry 164, 494-500.
84. Izquierdo I, Medina JH, Izquierdo LA, Barros DM, de Souza MM, Mello E, Souza T (1998). Short-and long-term memory are differentially regulated by monoaminergic systems in the rat brain. Neurobiology of Learning and Memory 69 (3), 219-224.
85. 2 antagonist properties. Journal of Pharmacology and Experimental Therapeutics 244, 685-693.
86. Jenner P, Marsden CD (1986). Is the dopamine hypothesis of tardive dyskinesia completely wrong? Trends in Neuroscience 9, 259 [letter].
87. Jetter W, Poser U, Freeman RB, Markowitsch HJ (1986). A verbal long-term memory deficit in frontal lobe damaged patients. Cortex: 22, 229-242.
88. Kalsi G, Mankoo DS, Curtis D, Brynjolfsson J, Read T, Sharma T, Murphy P, Petursson H, Gurling HM (1995). Exclusion of linkage of schizophrenia to the gene for the dopamine D2 receptor (DRD2) and chromosome 11q translocation sites. Psychological Medicine 25, 531-537.
89. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind placebo comparison with chlorpromazine. Archives of General Psychiatry 45, 789-796.
90. Kay SR, Fizbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 2, 261-276.
91. Kay SR, Sevy S (1990). Pyramidal model of schizophrenia. Schizophrenia Bulletin 16, 537-545.
92. Kendler KS, Diehl SR (1993). The genetics of schizophrenia: a current genetic-epidemiological perspective. Schizophrenia Bulletin 19, 261-285.
93. Kendler KS, MacLean CJ, O'Neill FA, Burke J, Murphy B, Duke F, Shinkwin R, Easter SM, Webb BT, Zhang J, Walsh D, Straub RE (1996). Evidence for a schizophrenia vulnerability locus in the Irish study of high-density schizophrenia families. American Journal of Psychiatry 153, 1534-1540.
94. Keshavan MS, Schooler NR, Sweeney JA, Haas GL, Pettegrew JW (1998). Research and treatment strategies in first-episode psychoses. The Pittsburgh experience. British Journal of Psychiatry 172 (Suppl. 33), 60-65.
95. King DJ (1994). Psychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiatrica Scandinavica 38 (Suppl.), 53-58.
96. Koh SD (1978). Remembering of verbal materials by schizophrenic young adults. In: Schwartz S (Ed.). Language and Cognition in Schizophrenia (pp. 59-69). Hillsdale NJ: Erlbaum.
97. 4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Archives of General Psychiatry, 54, 567-573.
98. Kremen WS, Seidman LJ, Pepple JR, Lyons MJ, Tsuang MT, Faraone SV (1994). Neuropsychological risk indicators for schizophrenia: a review of family studies. Schizophrenia Bulletin 20, 103-119.
99. Kringlen E (1990). Genetic aspects of schizophrenia with special emphasis on twin research. In: Kringlen et al. (Eds.) Etiology of Mental Disorders (pp. 63-79). Oslo: Department of Psychiatry, University of Oslo.
100. Kruglyak L, Lander ES (1995). High-resolution genetic mapping of complex traits. American Journal of Human Genetics 56, 1212-1223.
101. Lenzenweger MF, Dworkin RH (1996). The dimensions of schizophrenia phenomenology: not one or two, at least three, perhaps four. British Journal of Psychiatry 168, 432-440.
102. Levelt WJ (1989). Speaking: From Intention to Articulation. Cambridge, MA: MIT Press.
103. Levinson DF, Mahtani MM, Nancarrow DJ, Brown DM, Kruglyak L, Kirby A, Hayward NK, Crowe RR, Andreasen NC, Black DW, Silverman JM, Endicott J, Sharpe L, Mohs RC, Siever LJ, Walters MK, Lennon DP, Jones HL, Nertney DA, Daly MJ, Gladis M, Mowry BJ (1998). Genome scan of schizophrenia. American Journal of Psychiatry 155 (6), 741-749.
104. Levy DL, Holzman PS, Matthysse S, Mendell NR (1994). Eye tracking and schizophrenia: a selective review. Schizophrenia Bulletin 20, 47-62.
105. Leysen JE, Janssen PM, Commeren HV, Wynants J, Pauwels PJ, Janssen A (1992). In vitro and in vivo receptor binding effects on monoamine turnover in rat brain region of the novel antipsychotics risperidone and ocapieridone. Molecular Pharmacology 41, 494-508.
106. Lichter JB, Barr CL, Kennedy JL, Van Tol HHM, Kidd KK, Livak KJ (1993). A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Human Molecular Genetics 2, 767-773.
107. Liddle PF (1998). The Thought, Language and Communication Index. Vancouver : University of British Columbia Schizophrenia Division.
108. Liddle PF, Morris DL (1991). Schizophrenic syndromes and frontal lobe performance. British Journal of Psychiatry 158, 340-345.
109. Lidow MS, Williams GV, Goldman-Rakic PS (1998). The cerebral cortex : a case for a common site of action of antipsychotics. Trends in Pharmacological Sciences 19, 136-140.
110. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J (1991). The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry 158, 503-510.
111. Liégeois J-F, Eyrolles L, Bruhwyler J, Delarge J (1988). Dopamine D4 receptors : a new opportunity for research on schizophrenia. Current Medicinal Chemistry 5, 77-100.
112. Lin MW, Curtis D, Williams N, Arranz M, Nanlo S, Collier D, McGuffin P, Murray R, Owen M, Gill M, Powell J (1995). Suggestive evidence for linkage of schizophrenia to markers on chromosome 13q14.1-q32. Psychiatric Genetics 5, 117-126.
113. Lindenmayer JP, Negron AE, Shah S, Lowinger R, Kennedy G, Bark N, Hyman R (1997). Cognitive deficits and psychopathology in elderly schizophrenic patients. American Journal of Geriatric Psychiatry 5 (1), 31-42.
114. Liu Q, Sobell JL, Heston LL, Sommer SS (1995). Screening the dopamine D1 receptor gene in 131 schizophrenics and eight alcoholics: identification of polymorphism but lack of functionally significant sequence changes. American Journal of Medical Genetics 60, 165-171.
115. Logie R, Baddeley A, Mane A, Donchin E, Sheptak R (1989). Working memory in the acquisition of complex cognitive skills. Acta Psychologica 71, 53-87.
116. Luciana M, Collins PF, Depue RA (1998). Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Cerebral Cortex 8 (3), 218-226.
117. Lysaker P, Bell M, Bioty S, Zito W (1996). Performance on the Wisconsin Card Sorting Test as a predictor of rehospitalization in schizophrenia. Journal of Nervous and Mental Disease 184, 319-321.
118. Lysaker P, Bell M, Bioty S, Zito W (1997). Cognitive impairment and substance abuse history as predictors of the temporal stability of negative symptoms in schizophrenia. Journal of Nervous and Mental Disease 185, 21-26.
119. Malmberg A, Jackson DM, Eriksson A, Mohell N (1993). Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B and D3 receptors. Molecular Pharmacology 43, 749-754.
120. Mant R, Williams J, Asherson P, Parfitt E, McGuffin P, Owen MJ (1994). Relationship between homozygosity at the dopamine D3 receptor gene and schizophrenia. American Journal of Medical Genetics 54 (1), 21-26.
121. McGlashan TH, Fenton WS (1992), The positive-negative distinction in schizophrenia. Archives of General Psychiatry 49, 63-72.
122. McGue M, Gottesman II, Rao DC (1983). The transmission of schizophrenia under a multifactorial threshold model. American Journal of Genetics 35, 1161-1178.
123. McGuffin P, Asherson P, Owen M, Farmer A (1994). The strength of the genetic effect. Is there room for an environmental influence in the aetiology of schizophrenia? British Journal of Psychiatry 164, 593-599.
124. McGuire PK, Quested DJ, Spence SA, Murray RM, Frith CD, Liddle PF (1998). Pathophysiology of 'positive' thought disorder in schizophrenia. British Journal of Psychiatry 173, 231-235.
125. McKenna PJ, Tamlyn D, Lund CE, Mortimer AM, Hammond S, Baddeley AD (1990). Amnesic syndrome in schizophrenia. Psychological Medicine 20, 967-972.
126. Meadow-Woodruff JH, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ (1997). Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Archives of General Psychiatry 54, 1089-1095.
127. Medallia A, Gold J, Merriam A (1988). The effects of neuroleptics on neuropsychological test results of schizophrenics. Archives of Clinical Neuropsychology 3, 249-271.
128. Meltzer HY (1991). The mechanism of action of novel atypic antipsychotic drugs. Schizophrenia Bulletin 17, 263-287.
129. Meltzer H, Okayli G (1995). The reduction of suicidality during clozapine treatment in neuroleptic resistant schizophrenics. American Journal of Psychiatry 152, 183-190.
130. Michaels CF, Turvey MT (1979). Central sources of visual masking: Indexing structures supporting seeing at a single, brief glance. Psychological Research 41, 1-61.
131. Mirsky AF, Lockhead SJ, Jones BP, Jugelmass S, Walsh D, Kendler KS (1992). On familial factors in the attentional deficit in schizophrenia: a review and report of two new subject samples. Journal of Psychiatric Research 26, 383-403.
132. 2 dopamine receptor gene region and schizophrenia. Archives of General Psychiatry 48, 643-647.
133. Moises HW, Yang L, Kristbjarnarson H, Wiese C, Byerley W, Macciardi F, Arolt V, Blackwood D, Liu X, Sjogren B, et al. (1995). An international two-stage genome-wide search for schizophrenia susceptibility genes. Nature Genetics 11 (3), 321-324.
134. 2 dopamine receptors produced by alternative RNA splicing. Nature 342, 926-929.
135. Morice R, Delahunty A (1996). Frontal/executive impairments in schizophrenia. Schizophrenia Bulletin 22, 125-137.
136. Morice R, McNicol D (1985). The comprehension and production of complex syntax in schizophrenia. Cortex 21, 567-580.
137. Morice R, McNicol D (1986). Language changes in ; schizophrenia: a limited replication. Schizophrenia Bulletin 12 (2), 239-251.
138. Mowry BJ, Sandkuijl LA, Crowe RR, Silverman JM, Mohs RC, Siever LJ, Endicott J, Sharpe L, Walters MK, Hayward NK, Levinson DF (1995). Schizophrenia susceptibility and chromosome 6p24-22. Nature Genetics 11, 233-234.
139. Murray HA (1943). Thematic Apperception Test Manual, Boston, MA: Harvard College.
140. 2 receptor affinity for drugs and inhibition of adenylyl cyclase. Molecular Pharmacology 39, 733-739.
141. Nuechterlein KH (1983). Signal detection in vigilance tasks and behavioral attributes among offspring of schizophrenic mothers and among hyperactive children. Journal of Abnormal Psycholog 92, 4-23.
142. Nuechterlein KH, Dawson ME, Green MF (1994). Information processing abnormalities as neuropsychological vulnerability indicators for schizophrenia. Acta Psychiatrica Scandinavica 90 (Suppl. 384), 71-79.
143. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (1997). Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385 (6617), 578-579.
144. Owen MJ, McGuffin P (1993). Association and linkage: complementary strategies for complex disorders. Journal of Medical Genetics 30, 638-639.
145. Park S, Holzman PS, Goldman-Rakic PS (1995). Spatial working memory deficits in the relatives of schizophrenic patients. Archives of General Psychiatry 52, 821-828.
146. Perlick D, Stastny P, Mattis S, Teresi J (1992). Contribution of family, cognitive and clinical dimensions to long-term outcome in schizophrenia. Schizophrenia Research 6, 257-265.
147. Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, Breier A, Linnoila M, Paul SM (1986). Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients: correlation with psychosis and response to neuroleptic treatment. Archives of General Psychiatry 43, 669-676.
148. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW (1997). Limbic selectivity of clozapine. Lancet 350, 490-491.
149. Pulver AE, Karayiorgou M, Wolyniec PS, Lasseter VK, Kasch L, Nestadt G, Antonarakis S, Housman D, Kazazian HH, Meyers D, Ott J, Lamacz M, Liang K-Y, Hanfelt J, Ulrich G, DeMarchi N, Ramu E, McHugh PR, Adler L, Thomas M, Carpenter WT, Manschreck T, Gordon CT, Kimberland M, Babb R, Puck J, Childs B (1994). Sequential strategy to identify a susceptibility gene for schizophrenia: report of potential linkage on chromosome 22q12-q13.1. Part 1. American Journal of Medical Genetics 54, 36-43.
150. Pulver AE, Lasseter VK, Kasch L, Wolyniec P, Nestadt G, Blouin J-L, Kimberland M, Babb R, Vourlis S, Chen H, Laliot M, Morris MA, Karayiorgou M, Ott J, Meyers D, Antonarakis SE, Housman D, Kazazian HH (1995). Schizophrenia: a genome scan targets chromosome 3p and 8p as potential sites of susceptibility genes. American journal of Medical Genetics 60, 252-260.
151. Regier DA, Boyd JH, Burke JD Jr, Rae DS, Myers JK, Kramer M, Robins LN, George LK, Karno M, Locke BZ (1988). One month prevalence of mental disorders in the US: based on five epidemiologic catchment area (ECA) sites. Archives of General Psychiatry 45, 977-986.
152. Reynolds GP, Mason S (1994). Are striatal dopamine D4 receptors increased in schizophrenia? Journal of Neurochemistry 63, 1576-1577.
153. Riley BP, Rajagopalan S, Mogudi-Carter M, Jenkins T, Williamson R (1996). No evidence for linkage of chromosome 6p markers to schizophrenia in Southern African Bantu-speaking families. Psychiatric Genetics 6, 41-49.
154. Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, Casacchia M (1997). Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatrica Scandinavica 95, 40-43.
155. Rosvold HE, Mirsky A, Sarason I, Bransome ED Jr, Beck LH (1956). A continuous performance test of brain damage. Journal of Consulting Psychology 20, 343-350.
156. Rowe EW, Shean G (1997). Card-Sort performance and syndromes of schizophrenia. Genetic, Social and General Psychology Monographs 123 (2), 197-209.
157. Rutschmann J, Cornblatt B, Erlenmeyer-Kimling L (1986). Sustained attention in children at risk for schizophrenia: findings with two visual continuous performance tests in a new sample. Journal of Abnormal Child Psychology 14, 365-385.
158. Saltz BL, Woerner MG, Kane JM, Lieberman JA, Alvir JM, Bergmann KJ, Blank K, Koblenzer J, Kahaner K (1991). Prospective study of tardive dyskinesia incidence in the elderly. Journal of the American Medical Association 266, 2402-2406.
159. Scherer J, Tatsch K, Schwarz J, Oertel WH, Konjarczyk M, Albus M (1994). D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatrica Scandinavica 90, 266-268.
160. Schizophrenia Collaborative Linkage Group (Chromosome 22) (1996). A combined analysis of D22S278 marker alleles in affected sib-pairs: support for a susceptibility locus for schizophrenia at chromosome 22q12. American Journal of Medical Genetics 67, 40-45.
161. Schizophrenia Linkage Collaborative Group for chromosomes 3, 6 and 8 (1996). Additional support for schizophrenia linkage on chromosomes 6 and 8: a multicenter study. American Journal of Medical Genetics 67, 580-594.
162. Schmauss C, Haroutunian V, Davis K, Davidson M (1993). Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proceedings of the National Academy of Sciences, USA 90, 8942-8946.
163. Schreiber H, Stolz-Born G, Heinrich H, Kornhuber HH, Born J (1992). Attention, cognition and motor perseveration in adolescents of genetic risk for schizophrenia and control subjects. Psychiatry Research 44, 125-140.
164. Schult W, Apicella P, Ljungberg T (1993). Responses of monkey dopamine neurons to reward and conditioned stimuli during successive steps of learning a delayed response task. Journal of Neuroscience 13, 900-913.
165. Schwab SG, Eckstein GN, Hallmayer J, Lerer B, Albus M, Borrmann M, Lichtermann D, Ertl MA, Maier W, Wildenauer DB (1997). Evidence suggestive of a locus on chromosome 5q31 contributing to susceptibility in German and Israeli families by multipoint affected sib-pair linkage analysis. Molecular Psychiatry 2, 156-160.
166. Schwab SG, Albus M, Hallmayer J, Hönog S, Borrmann M, Lichterman D, Ebstein RP, Ackenheil M, Lerer B, Risch N et al. (1995). Evaluation of a susceptibility gene for schizophrenia on chromosome 6p by multipoint affected sib-pair linkage analysis. Nature Genetics 11, 325-327.
167. Schwartz J, Giro B, Martres MP, Sokoloff P (1992). The dopamine receptor family: molecular biology and pharmacology. Neuroscience 4, 99-108.
168. Seamans JK, Floresco SB, Phillips AG (1998). D1 receptor modulation of hippocampal-prefrontal cortical circuits integrating spatial memory with executive functions in the rat. Journal of Neuroscience 18 (4), 1613-1621.
169. Seeman P (1987). Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1, 133-152.
170. Seeman P, Van Tol HHM (1994). Dopamine receptors. Trends in Pharmacological Science 15, 264-270.
171. Seeman P, Van Tol HHM (1993). Dopamine receptor pharmacology. Current Opinion in Neurology and Neurosurgery 6, 602-608.
172. Seeman P, Corbett R, Van Tol HHM (1998). Dopamine D4 receptors may alleviate antipsychotic-induced Parkinsonism. Advances in Pharmacology 42, 478-482.
173. Seeman P, Guan HC, van Tol H (1993). Dopamine D4 receptor elevated in schizophrenia. Nature 365, 441-445.
174. Seeman P, Ulpian C, Chouinard G, Van Tol HHM, Dwosh H, Lieberman JA, Siminovitch K, Liu ISC, Waye J, Voruganti P, Hudson C, Serjeant GR, Masibay AS, Seeman MV (1994). Dopamine D4 receptor variant, D4glycine194, in Africans, but not in Caucasians: no association with Schizophrenia. American Journal of Medical Genetics (Neuropsychiatric Genetics) 54, 384-390.
175. Shallice T, Fletcher P, Frith CD, Grasby P, Frackowiak RS, Dolan RJ (1994). Brain regions associated with acquisition and retrieval of verbal episodic memory. Nature 368, 633.
176. Sobell JL, Lind TJ, Sigurdson DC, Zald DH, Snitz BE, Grove WM, Heston LL, Dommer SS (1995). The D5 dopamine receptor gene in schizophrenia: identification of a nonsense change and multiple missense changes but lack of association with disease. Human Molecular Genetics 4 (4), 507-514.
177. Sokoloff P, Giros B, Martres MP, Barthenet ML, Schwartz JC (1990). Molecular cloning and characterization of a novel dopamine receptor (D-3) as a target for neuroleptics. Nature 347, 146-151.
178. Spurlock G, Williams J, McGuffin P, Aschauer HN, Lenzinger E, Fuchs K, Sieghart WC, Meszaros K, Fathi N, Laurent C, Mallet J, Macciardi F, Pedrini S, Gill M, Hawi Z, Gibson S, Jazin EE, Yang H-T, Adofsson R, Pato CN, Dourado AM, Owen MJ (1998). European multicentre association study of schizophrenia: a study of the DRD2 Ser311Cys and DRD3 Ser9Gly polymorphisms. American Journal of Medical Genetics (Neuropsychiatric Genetics), 81, 24-28.
179. Steinhauer SR, Zubin J, Condray R, Shaw DB, Peters JL, Van Kammen DP (1991). Electrophysiological and behavioral signs of attentional disturbance in schizophrenics and their siblings. In: Tamminga CA, Schulz SC (Eds), Schizophrenia Research: Advances in Neuropsychiatry and Psychopharmacology, vol. 1 (pp. 169-178). New York: Raven Press.
180. Stip E, Lussier I (1996). The effect of risperidone on cognition in patients with schizophrenia. Canadian Journal of Psychiatry 41 (Suppl. 2), 35S-40S.
181. Stip E, Lussier I, Babai M, Fabian JL (1996). Seroquel and cognitive improvement in patients with schizophrenia. Biological Psychiatry 40, 430-437.
182. Straub RE, MacLean CJ, O'Neill FA, Burke J, Murphy B, Duke F, Shinkwin R, Webb BT, Zhang J, Walsh D et al. (1995). A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity. Nature Genetics 11, 287-293.
183. Straub RE, MacLean CJ, O'Neill FA, Walsh D, Kendler KS (1997). Support for a schizophrenia vulnerability locus in region 5q21-q31 in Irish pedigrees. Molecular Psychiatry 2, 148-155.
184. Suzuki M, Hurd YL, Sokoloff P, Schwartz JC, Sedvall G (1998). D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Research 779 (1-2), 58-74.
185. Szymanski S, Masiar S, Mayerhoff D, Loebel A, Geisler S, Pollack S, Kane J, Lieberman J (1994). Clozapine response in treatment refractory first episode schizophrenia. Biological Psychiatry 35, 278-280.
186. Tamlyn D, McKenna CJ, Morgentheimer AN, Lund CE, Hammond S, Baddeley AD (1992). Memory impairment in schizophrenia: its extent, affiliations, and neuropsychological character. Psychological Medicine 22, 101-115.
187. Taylor S, Komblum S, Tandon R (1996). Facilitation and interference of selective attention in schizophrenia. Psychiatry Research 30, 251-259.
188. Thornley B, Adams C (1998). Content and quality of 2000 controlled trials in schizophrenia over 50 years. British Medical Journal 317, 1181-1184.
189. Ukai M, Tanaka T, Kameyama T (1997). Effects of the dopamine D3 receptor agonist, R(+)-7-hydroxy-N,N-di-n-propyl-2-aminotetralin, on memory processes mice. European Journal of the Pharmacology 324 (2-3), 147-151.
190. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350, 610-614.
191. Van Tol HHM, Seeman P (1995). The dopamine D4 receptors: a novel site for antipsychotic action. Clinical Neuropharmacology 18 (Suppl. 1), S143-S153.
192. Van Tol HHM, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V (1992). Multiple dopamine D4 receptor variants in the human population. Nature 358, 149-152.
193. Volkow ND, Gur RC, Wang GJ, Fowler JS, Moberg PJ, Ding YS, Hitzemann R, Smith G, Logan J (1998). Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. American Journal of Psychiatry 155 (3), 344-349.
194. Wang S, Sun C, Walszak CA, Ziegle JS, Kipps BR, Goldin LR, Diehl SR (1995). Evidence for a susceptibility locus for schizophrenia on chromosome 6pter-p22. Nature Genetics 10, 41-46.
195. Weinberger DR (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry 44, 660-669.
196. Weinberger DB, Berman KF, Zec RF (1986). Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Archives of General Psychiatry 43, 114-125.
197. Wexler BE, Stevens AA, Bowers AA, Sernyak MJ, Goldman-Rakic PS (1998). Word and Tone memory deficits in schizophrenia. Archives of General Psychiatry 55, 1093-1096.
198. Williams J, Spurlock G, Holmans P, Mant R, Murphy K, Jones L, Cardno A, Asherson P, Blackwood D, Muir W, Meszaros K, Aschauer H, Mallet J, Laurent C, Pekkarinen P, Seppala J, Stefanis CN, Papadimitriou GN, Macciardi F, Verga M, Pato C, Azevedo H, Crocq M-A, Gurling H, Kalsi G, Curtis D, McGuffin P, Owen MJ (1998). A meta-analysis and transmission disequilibrium study of association between the dopamine D3 receptor gene and schizophrenia. Molecular Psychiatry 3 (2) 141-149.
199. Wood RL, Cook M (1979). Attentional deficit in the siblings of schizophrenics. Psychological Medicine 9, 465-467.
200. Yang L, Li T, Wiese C, Lannfelt L, Sokoloff P, Xu CT, Zeng Z, Schwartz JC, Liu X, Moises HW (1993). No association between schizophrenia and homozygosity at the D3 dopamine receptor gene. American Journal of Medical Genetics 48 (2), 83-86.
201. Zahrt J, Taylor JR, Mathew RG, Amsten AF (1997). Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. Journal of Neuroscience 17 (21), 8528-8535.